Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132886 · ClinicalTrials.gov registry record · Phase 2
Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure
A Phase 2 study of Heart Failure, Congestive, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT00132886: Completed Phase 2 study of Heart Failure, Congestive, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT00132886 is a Phase 2 study of Heart Failure, Congestive that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 140 participants, below the 671-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00132886, a Phase 2 study of Heart Failure, Congestive, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how a single dose of study medication (tolvaptan) versus an inactive sugar pill (placebo) effect pressures in the heart in patients with congestive heart failure. Higher than normal pressures can be related to symptoms of heart failure (shortness of breath, fatigue, etc.).
Conditions Studied
Interventions
- DRUG tolvaptan
Study Locations (20)
Florida
- Broward General Medical Center - Fort Lauderdale
- Cardiovascular Center at Shands Jacksonville - Jacksonville
- Tampa General Hospital - Tampa
Illinois
- Northwestern University - Chicago
- Robert Rush University Medical Center - Chicago
- Loyola University of Chicago - Maywood
California
- Merced Heart Associates - Merced
- Olive View-UCLA Medical Center - Sylmar
Louisiana
- Cardiologist Institute - Slidell
- Medical Research Institute Louisiana Heart Hospital - Slidell
Massachusetts
- Primary Cardiology Associates - Ayer
- U-MASS Memorial Medical Center - Worchester
Alabama
- Oracle Research, A Div of the Heart Center - Huntsville
Georgia
- ACRI - Atlanta
Iowa
- University of Iowa Health Care - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
What the finished NCT00132886 record still lists
NCT00132886 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 671-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 1 intervention - of which tolvaptan is the first listed.
NCT00132886 names 20 study sites across 13 states, led by Florida, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT00132886 about?
NCT00132886 is a clinical study titled "Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure". This study will look at how a single dose of study medication (tolvaptan) versus an inactive sugar pill (placebo) effect pressures in the heart in patients with congestive heart failure. Higher than normal pressures can be related to symptoms of heart failure (shortness of breath, fatigue, etc.).
What is the current status of trial NCT00132886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2004-12. Estimated completion is 2006-12.
What conditions does trial NCT00132886 study?
This clinical trial studies the following conditions: Heart Failure, Congestive.
What interventions are being tested in trial NCT00132886?
The interventions under investigation include: tolvaptan (DRUG).
Who is sponsoring clinical trial NCT00132886?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00132886 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure, Congestive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00132886's enrollment target sits among peer trials
140 22nd of 39 higher than 18 of 39 other Heart Failure, Congestive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure, Congestive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise After an ICD
COMPLETED · Phase 2
-
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
COMPLETED · Phase 2
-
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
COMPLETED · Phase 2
-
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
COMPLETED · Phase 2
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia